PL372425A1 - Pochodne III dihydrobenzodiazepin-2-onu - Google Patents
Pochodne III dihydrobenzodiazepin-2-onuInfo
- Publication number
- PL372425A1 PL372425A1 PL03372425A PL37242503A PL372425A1 PL 372425 A1 PL372425 A1 PL 372425A1 PL 03372425 A PL03372425 A PL 03372425A PL 37242503 A PL37242503 A PL 37242503A PL 372425 A1 PL372425 A1 PL 372425A1
- Authority
- PL
- Poland
- Prior art keywords
- dihydrobenzodiazepin
- derivatives
- treatment
- neurological disorders
- neurological
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02002012 | 2002-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL372425A1 true PL372425A1 (pl) | 2005-07-25 |
Family
ID=27675598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03372425A PL372425A1 (pl) | 2002-02-06 | 2003-01-28 | Pochodne III dihydrobenzodiazepin-2-onu |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6949542B2 (pl) |
| EP (1) | EP1474416B1 (pl) |
| JP (1) | JP4077411B2 (pl) |
| KR (1) | KR20040081486A (pl) |
| CN (1) | CN100497333C (pl) |
| AR (1) | AR038481A1 (pl) |
| AT (1) | ATE374196T1 (pl) |
| AU (1) | AU2003205695B8 (pl) |
| BR (1) | BR0307474A (pl) |
| CA (1) | CA2474219C (pl) |
| DE (1) | DE60316538T2 (pl) |
| DK (1) | DK1474416T3 (pl) |
| ES (1) | ES2294264T3 (pl) |
| GT (1) | GT200300028A (pl) |
| HK (1) | HK1078858A1 (pl) |
| HR (1) | HRP20040678A2 (pl) |
| IL (1) | IL163102A (pl) |
| MX (1) | MXPA04007516A (pl) |
| MY (1) | MY176608A (pl) |
| NO (1) | NO327697B1 (pl) |
| NZ (1) | NZ534122A (pl) |
| PA (1) | PA8565901A1 (pl) |
| PE (1) | PE20031011A1 (pl) |
| PL (1) | PL372425A1 (pl) |
| PT (1) | PT1474416E (pl) |
| RU (1) | RU2315764C2 (pl) |
| SI (1) | SI1474416T1 (pl) |
| TW (1) | TWI326599B (pl) |
| UY (1) | UY27654A1 (pl) |
| WO (1) | WO2003066623A1 (pl) |
| ZA (1) | ZA200406032B (pl) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200201026T2 (tr) * | 1999-10-15 | 2002-08-21 | F.Hoffmann-La Roche Ag | Benzodiazepin türevleri |
| CA2532347C (en) * | 2003-07-25 | 2012-03-27 | F. Hoffmann-La Roche Ag | Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
| AU2006298829B2 (en) | 2005-09-27 | 2011-03-03 | F. Hoffmann-La Roche Ag | Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| WO2008128889A1 (en) * | 2007-04-19 | 2008-10-30 | F. Hoffmann-La Roche Ag | Dihydro-benzo[b][1,4]diazepin-2-one sulfonamide derivatives |
| MX2010002341A (es) | 2007-08-27 | 2010-03-22 | Hoffmann La Roche | Derivados de bencimidazol usados como agonistas del receptor x de farnesoide. |
| NZ584152A (en) | 2007-09-14 | 2011-11-25 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
| PT2203439E (pt) | 2007-09-14 | 2011-02-11 | Ortho Mcneil Janssen Pharm | 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas |
| JP5433579B2 (ja) | 2007-09-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | １，３−二置換−４−フェニル−１ｈ−ピリジン−２−オン |
| MX2010005110A (es) | 2007-11-14 | 2010-09-09 | Ortho Mcneil Janssen Pharm | Derivados de imidazo[1,2-a]piridina y su uso como moduladores alostericos positivos de los receptores de glutamato metabotropico 2. |
| EP2331095B1 (en) | 2008-08-04 | 2014-10-15 | CHDI Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| BRPI0918055A2 (pt) | 2008-09-02 | 2015-12-01 | Addex Pharmaceuticals Sa | derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato. |
| CA2738849C (en) | 2008-10-16 | 2016-06-28 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| TWI481601B (zh) | 2009-08-21 | 2015-04-21 | Otsuka Pharma Co Ltd | 含氮化合物及藥學組成物 |
| IN2012DN00986A (pl) | 2009-08-21 | 2015-04-10 | Otsuka Pharma Co Ltd | |
| CN102811620B (zh) | 2010-01-25 | 2015-03-25 | Chdi基金会股份有限公司 | 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法 |
| US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
| CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| WO2012149540A1 (en) | 2011-04-28 | 2012-11-01 | The Broad Institute Inc | Inhibitors of histone deacetylase |
| WO2013033246A2 (en) | 2011-08-29 | 2013-03-07 | Braincells, Inc. | Novel benzodiazepinones as modulators of metabotropic glutamate receptor functions and neurological uses thereof |
| PL2750677T3 (pl) | 2011-08-30 | 2017-12-29 | Chdi Foundation, Inc. | Inhibitory 3-monooksygenazy kinureninowej, kompozycje farmaceutyczne i sposoby ich stosowania |
| BR112014004845A2 (pt) | 2011-08-30 | 2017-04-04 | Chdi Foundation Inc | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada |
| CA2880117C (en) | 2012-07-27 | 2021-04-06 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| WO2014064028A1 (en) | 2012-10-23 | 2014-05-01 | F. Hoffmann-La Roche Ag | Mglu2/3 antagonists for the treatment of autistic disorders |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| SI3096790T1 (sl) | 2014-01-21 | 2019-11-29 | Janssen Pharmaceutica Nv | Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba |
| ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
| CA2943877A1 (en) | 2014-04-23 | 2015-10-29 | F. Hoffmann-La Roche Ag | Mglu2/3 antagonists for the treatment of intellectual disabilities |
| WO2015191630A1 (en) * | 2014-06-10 | 2015-12-17 | Sanford-Burnham Medical Research Institute | Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof |
| BR112017000922A2 (pt) | 2014-07-17 | 2018-01-16 | Chdi Foundation, Inc. | métodos e composições para tratar distúrbios relacionados ao hiv |
| JP2017206438A (ja) * | 2014-08-22 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | テトラヒドロイミダゾ［１，５−ｄ］［１，４］オキサゼピン化合物（ＴＥＴＲＡＨＹＤＲＯＩＭＩＤＡＺＯ［１，５−ｄ］［１，４］ＯＸＡＺＥＰＩＮＥＣＯＭＰＯＵＮＤ） |
| WO2018019721A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| WO2018019755A1 (en) | 2016-07-26 | 2018-02-01 | Basf Se | Herbicidal pyridine compounds |
| CN110407740A (zh) * | 2019-09-04 | 2019-11-05 | 上海毕得医药科技有限公司 | 一种3-溴-2-乙基吡啶的合成方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69008906T2 (de) * | 1989-03-23 | 1994-08-25 | Pfizer | Antiallergische Mittel auf der Basis von Diazepin. |
| IL148816A0 (en) | 1999-10-15 | 2002-09-12 | Hoffmann La Roche | Benzodiazepine derivatives |
| TR200201026T2 (tr) | 1999-10-15 | 2002-08-21 | F.Hoffmann-La Roche Ag | Benzodiazepin türevleri |
-
2003
- 2003-01-24 US US10/350,713 patent/US6949542B2/en not_active Expired - Lifetime
- 2003-01-28 RU RU2004126945/04A patent/RU2315764C2/ru not_active IP Right Cessation
- 2003-01-28 DK DK03702549T patent/DK1474416T3/da active
- 2003-01-28 PT PT03702549T patent/PT1474416E/pt unknown
- 2003-01-28 CA CA2474219A patent/CA2474219C/en not_active Expired - Fee Related
- 2003-01-28 CN CNB038065452A patent/CN100497333C/zh not_active Expired - Fee Related
- 2003-01-28 EP EP03702549A patent/EP1474416B1/en not_active Expired - Lifetime
- 2003-01-28 SI SI200331034T patent/SI1474416T1/sl unknown
- 2003-01-28 WO PCT/EP2003/000859 patent/WO2003066623A1/en active IP Right Grant
- 2003-01-28 AU AU2003205695A patent/AU2003205695B8/en not_active Ceased
- 2003-01-28 BR BR0307474-9A patent/BR0307474A/pt not_active Application Discontinuation
- 2003-01-28 ES ES03702549T patent/ES2294264T3/es not_active Expired - Lifetime
- 2003-01-28 JP JP2003565996A patent/JP4077411B2/ja not_active Expired - Fee Related
- 2003-01-28 MX MXPA04007516A patent/MXPA04007516A/es active IP Right Grant
- 2003-01-28 KR KR10-2004-7012084A patent/KR20040081486A/ko active Search and Examination
- 2003-01-28 PL PL03372425A patent/PL372425A1/pl not_active Application Discontinuation
- 2003-01-28 NZ NZ534122A patent/NZ534122A/en not_active IP Right Cessation
- 2003-01-28 DE DE60316538T patent/DE60316538T2/de not_active Expired - Lifetime
- 2003-01-28 AT AT03702549T patent/ATE374196T1/de active
- 2003-01-30 TW TW092102234A patent/TWI326599B/zh active
- 2003-02-03 GT GT200300028A patent/GT200300028A/es unknown
- 2003-02-03 PE PE2003000122A patent/PE20031011A1/es not_active Application Discontinuation
- 2003-02-04 AR ARP030100334A patent/AR038481A1/es unknown
- 2003-02-05 PA PA20038565901A patent/PA8565901A1/es unknown
- 2003-02-05 UY UY27654A patent/UY27654A1/es not_active Application Discontinuation
- 2003-02-05 MY MYPI20030378A patent/MY176608A/en unknown
-
2004
- 2004-07-19 IL IL163102A patent/IL163102A/en not_active IP Right Cessation
- 2004-07-23 HR HR20040678A patent/HRP20040678A2/hr not_active Application Discontinuation
- 2004-07-28 ZA ZA200406032A patent/ZA200406032B/en unknown
- 2004-08-02 NO NO20043237A patent/NO327697B1/no not_active IP Right Cessation
-
2005
- 2005-11-25 HK HK05110731.8A patent/HK1078858A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1474416T1 (sl) | Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj | |
| IL169091A0 (en) | Benzazepine derivatives for the treatment of neurological disorders | |
| IL175055A0 (en) | Combinations useful for the treatment of neuronal disorders | |
| AU2003286567A8 (en) | Methods for the treatment of skin disorders | |
| ZA200401004B (en) | Combination for the treatment of inflammatory disorders | |
| HK1092367A1 (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| IL176581A0 (en) | Immunomodulatory compounds for the treatment of central nervous system disorders | |
| IL209842A0 (en) | Compounds for the treatment of metabolic disorders | |
| AU2003249983A8 (en) | Piperidines useful for the treatment of central nervous system disorders | |
| AU2002356525A1 (en) | Substituted amines for the treatment of neurological disorders | |
| AP2005003274A0 (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| IL153425A0 (en) | Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders | |
| AU2003274342A8 (en) | Compositions for the treatment of autoimmune disorders | |
| IL162485A0 (en) | Compounds for the treatment of inflammatory disorders | |
| EP1617844A4 (en) | TREATMENT OF NEUROLOGICAL DISEASES | |
| AU2003228819A8 (en) | Combinations for the treatment of inflammatory skin disorders | |
| EP1658072A4 (en) | Compounds for the Treatment of Neurodegenerative Diseases | |
| AU2003286728A8 (en) | Compounds for the treatment of metabolic disorders | |
| HRP20041160A2 (en) | Novel combination for the treatment of airway disorders | |
| AU2003274885A1 (en) | Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders | |
| HRP20041159A2 (en) | Combination for the treatment of airway disorders | |
| GB0216097D0 (en) | Treatment of proliferative disorders | |
| AU2002322397A1 (en) | Combination therapy for the treatment of neurological disorders | |
| GB0213575D0 (en) | Treatment for movement disorders | |
| ZA200508341B (en) | Agents for the treatment of lower abdominal disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |